

REC'D PCT/PTO 06 DEC 2005

INTERNATIONAL SEARCH REPORT

International Application No
PCT/HU2004/000077

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61K31/42 C07D231/12

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 A61K C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, BEILSTEIN Data, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	JOSH J. YUAN ET AL.: "Disposition of a specific cyclooxygenase-2 inhibitor, valdecoxib, in human" DRUG METABOLISM AND DISPOSITION, vol. 30, no. 9, 2002, pages 1013-1021, XP002311618	1,2,6,7
Y	cited in the application abstract; figure 5 page 1018, column 2, paragraph 2 ----- -/--	1-7, 14-21

☒ Further documents are listed in the continuation of box C.

☐ Patent family members are listed in annex.

* Special categories of cited documents:

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

G document member of the same patent family

Date of the actual completion of the international search

21 December 2004

Date of mailing of the international search report

20/01/2005

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Molina de Alba, J

INTERNATIONAL SEARCH REPORT

International Application No
PCT/HU2004/000077

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	JOHN J. TALLEY ET AL.: "4-'5-Methyl-3-phenylisoxazol-4-yl'-benzen esulfonamide, Valdecoxib: A potent and selective inhibitor of COX-2" J.MED.CHEM., vol. 43, 2000, pages 775-777, XP002311619 page 776, column 2, paragraph 2 - paragraph 3; compounds 2,3	1-21
Y	HERBERT T. NAGASAWA ET AL.: "Carbethoxylating agents as inhibitors of aldehyde dehydrogenase" J.MED.CHEM., vol. 38, 1995, pages 1872-1876, XP002311620 page 1875, column 1, last paragraph	8-13
Y	MAURICE L. MOORE ET AL.: "Substituted sulfanilamides. III. N4-Acyl-N1-hydroxy derivatives" J.AM.CHEM.SOC., vol. 62, 1940, pages 2097-2099, XP002311621 page 2098, column 1, paragraph 2 - paragraph 3	8-13
A	JI Y. ZHANG ET AL.: "Pharmacokinetics and metabolism of a COX-2 inhibitor, valdecoxib, in mice" DRUG METABOLISME AND DISPOSITION, vol. 31, no. 4, April 2003 (2003-04), pages 491-501, XP002311622 page 501, column 1, last paragraph - column 2, paragraph 1; figure 8	1-21
A	DATABASE CAPLUS 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; SARAPA, NENAD ET AL: "Valdecoxib, a COX-2-specific inhibitor, does not affect cardiac repolarization" XP002311623 retrieved from STN Database accession no. 2003:753917 abstract & JOURNAL OF CLINICAL PHARMACOLOGY , 43(9), 974-982 CODEN: JCPCBR; ISSN: 0091-2700, 2003,	14-21